Current - 4 hours ago

Skip to main content

Close Search

search

Menu

* Approach

* Portfolio

* Team

* News & Insights

+ News

+ Insights

* Contact

* search

Venture the Path Less TraveledTM

A healthcare venture capital firm rooted in the Midwest

Improving patient outcomes, reducing healthcare costs

Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.

View our portfolio

Medical Devices

Life Science Tools

& Diagnostics

Tech-Enabled

Care Delivery

Pharma

Adjacencies

Entrepreneurs

We seek innovations that solve (big) healthcare problems and make a transformational impact from teams who are diverse in thought, geography, and demographics.

Investors

We have a proven formula for identifying early-stage startups that can create value in a capital-efficient manner, accelerate portfolio value, and deliver superior returns.

Your path to success

Portfolio Spotlight

We invest in today’s ideas to forge a path for better healthcare tomorrow

Where NeuMoDx started?

Molecular diagnostics is one of the fastest-growing segments within the in-vitro diagnostics market, but existing systems are expensive, complex, and lack sophisticated automation. Through a unique combination of automation and microfluidics, the NeuMoDx Molecular clinical PCR systems offer best-in-class ease of use, throughput, and cost per test.

Where NeuMoDx is today?

Arboretum collaborated with the team to set the strategic direction that helped accelerate the company’s product development timeline and helped recruit new investors. Since Arboretum’s investment, NeuMoDx gained regulatory approvals for its first assays, launched its product, and in September 2020, QIAGEN acquired NeuMoDx to strengthen its portfolio of automated molecular testing.

Ready to grow with us?

We fuel the future of healthcare

1B

under management across six funds

76

of the portfolio invested in under-ventured markets over 20 years

45

of all active companies have either a female / minority CEO or founder

16

patient - lives impacted

View portfolio

Shifting the venture capital paradigm

We are proud to be a Midwest venture capital firm operating with transparency, integrity, and approachability to help you realize your entrepreneurial and investor goals. Together, we’ll positively impact patients, communities, and healthcare.

Meet your team

Testimonials

“

I’ve worked with many venture capital investors over my career, but Tom Shehab and the team at Arboretum Ventures are more than investors; they're proactive, involved partners. They collaborate with us, leaning in to tackle challenges shoulder to shoulder. Their steady devotion and vast network have been catalysts for our growth in advancing neuromodulation for autoimmune diseases.

Heather Simonsen CEO – Boomerang Medical

“

Dan Kidle and the Arboretum team have exhibited profound dedication to nurturing our company's growth as we seek to revolutionize care for critically ill patients. Their involvement extends beyond just friendly advice; they are integral to our strategic decision-making process, offering invaluable insights, guidance, and connections.

Joe Eibl CEO – Flosonics Medical

“

Jan is a leading advocate for innovations in healthcare across our world. Her focus and dedication to enable innovation in medical devices in particular, have had great impacts in human lives across various disease states. At Koya, as we focus on transforming venous and lymphatic care, having Jan not only invest through Arboretum but also provide her counsel, advocacy, and wisdom has greatly enabled our path forward. I am personally grateful for Jan’s support and strength that any founder or CEO would desire.

Andy Doraiswamy PhD CEO – Koya Medical

“

Beyond providing growth capital, Tim Petersen and Arboretum Ventures have quickly become an indispensable partner to Convergent Dental. Their contributions range from Tim’s thoughtful leadership on our board to making their impressive advisory board available to me to gain their insights on a variety of strategic topics. In fact, following a recent presentation to their advisory board, one of the members made himself available for a 1:1 mentoring discussion that materially influenced a recent transaction that are in the process of completing.

Rob Gershon CEO – Convergent Dental

“

Paul McCreadie and the Arboretum team bring a solid foundation of investing experience and a deep network of industry partners that have helped shape our development strategy at Allay. I can rely on his consistent support and thoughtful approach to board discussions whether things are going well or if we are facing challenges.

Adam Gridley CEO – Allay Therapeutics

In the News

September 4, 2024 in Home Page , Koya Medical , News Page

Koya Medical Announces TEAYS Study: Dayspring Outperforms Pneumatic Compression Devices for Lower Extremity Lymphedema

Koya Medical, a healthcare company with a mission to transform venous and lymphatic treatments through novel, people-centric solutions, today announced that the full results from the TEAYS (Treatment Effectiveness of…

Read More

August 14, 2024 in Arboretum , Home Page , News Page

Tim Petersen to Receive Hall of Fame Award at the Michigan Venture Capital Association’s Yearly Awards Celebration

Michigan Venture Capital Association (MVCA), the trade association for the venture capital and angel community in Michigan, today announced the nominees for the 2024 MVCA Annual Awards Celebration.

Read More

July 30, 2024 in Home Page , News Page , ViaLase

ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it has received CE (Conformité Européenne) Mark approval in the…

Read More

Read all news

Subscribe to our newsletter

303 Detroit Street

Suite 301

Ann Arbor, MI 48104

734.998.3688

info@arboretumvc.com

Home

Approach

Portfolio

News

Insights

Contact Us

© 2024 Arboretum Ventures. Privacy Policy | Cookie Policy | Terms Policy

* linkedin

* email

Close Menu

* Approach

* Portfolio

* Team

* News & Insights

+ News

+ Insights

* Contact

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked. OkNoPrivacy Policy